Pärt Peterson

Prof. Pärt Peterson

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Science
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
LRLindsey B. Rosen
Lindsey B. Rosen
QZQian Zhang
Qian Zhang
EMEleftherios Michailidis
Eleftherios Michailidis
HHHans-Heinrich Hoffmann
Hans-Heinrich Hoffmann
JCJean-Laurent Casanova
Jean-Laurent Casanova
The genetics underlying severe COVID-19: The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science , this issue p. eabd4570 , p. eabd4585 ; see also p. 404

1 December 1997 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KNKentaro Nagamine
Kentaro Nagamine
PPPärt Peterson
Pärt Peterson
HSHamish S Scott
Hamish S Scott
JKJun Kudoh
Jun Kudoh
SMShinsei Minoshima
Shinsei Minoshima
NSNobuyoshi Shimizu
Nobuyoshi Shimizu

21 October 2019 in European Journal of Immunology
Verified
Journal Article
Open access
ACAndrea Cossarizza
Andrea Cossarizza
HCHyun-Dong Chang
Hyun-Dong Chang
ARAndreas Radbruch
Andreas Radbruch
AAAndreas Acs
Andreas Acs
DADieter Adam
Dieter Adam
AZArturo Zychlinsky
Arturo Zychlinsky
These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer‐reviewed by leading experts in the field, making this an essential research companion.

17 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAdam G. Laing
Adam G. Laing
ALAnna Lorenc
Anna Lorenc
IBIrene del Molino del Barrio
Irene del Molino del Barrio
ADAbhishek Das
Abhishek Das
MFMatthew Fish
Matthew Fish
AHAdrian C. Hayday
Adrian C. Hayday

22 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarjolein J. Peters
Marjolein J. Peters
RJRoby Joehanes
Roby Joehanes
LPLuke Pilling
Luke Pilling
CSClaudia Schurmann
Claudia Schurmann
KCKaren N. Conneely
Karen N. Conneely
AJAndrew D. Johnson
Andrew D. Johnson
Disease incidences increase with age, but the molecular characteristics of ageing that lead to increased disease susceptibility remain inadequately understood. Here we perform a whole-blood gene expression meta-analysis in 14,983 individuals of European ancestry (including replication) and identify 1,497 genes that are differentially expressed with chronological age. The age-associated genes do not harbor more age-associated CpG-methylation sites than other genes, but are instead enriched for the presence of potentially functional CpG-methylation sites in enhancer and insulator regions that associate with both chronological age and gene expression levels. We further used the gene expression profiles to calculate the ‘transcriptomic age’ of an individual, and show that differences between transcriptomic age and chronological age are associated with biological features linked to ageing, such as blood pressure, cholesterol levels, fasting glucose, and body mass index. The transcriptomic prediction model adds biological relevance and complements existing epigenetic prediction models, and can be used by others to calculate transcriptomic age in external cohorts.

1 February 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
KKKalle Kisand
Kalle Kisand
AWAnette S. Bøe Wolff
Anette S. Bøe Wolff
KPKatarina Trebušak Podkrajšek
Katarina Trebušak Podkrajšek
LTLiina Tserel
Liina Tserel
MLMaire Link
Maire Link
AMAnthony Meager
Anthony Meager
Chronic mucocutaneous candidiasis (CMC) is frequently associated with T cell immunodeficiencies. Specifically, the proinflammatory IL-17A–producing Th17 subset is implicated in protection against fungi at epithelial surfaces. In autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED, or autoimmune polyendocrine syndrome 1), CMC is often the first sign, but the underlying immunodeficiency is a long-standing puzzle. In contrast, the subsequent endocrine features are clearly autoimmune, resulting from defects in thymic self-tolerance induction caused by mutations in the autoimmune regulator (AIRE). We report severely reduced IL-17F and IL-22 responses to both Candida albicans antigens and polyclonal stimulation in APECED patients with CMC. Surprisingly, these reductions are strongly associated with neutralizing autoantibodies to IL-17F and IL-22, whereas responses were normal and autoantibodies infrequent in APECED patients without CMC. Our multicenter survey revealed neutralizing autoantibodies against IL-17A (41%), IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients, especially those with CMC. We independently found autoantibodies against these Th17-produced cytokines in rare thymoma patients with CMC. The autoantibodies preceded the CMC in all informative cases. We conclude that IL-22 and IL-17F are key natural defenders against CMC and that the immunodeficiency underlying CMC in both patient groups has an autoimmune basis.